BRAF and pilocytic astrocytoma: For other entities, although the diagnosis does not yet require the characterization of the underlying molecular abnormalities, it is nevertheless specified in the 2016 WHO classification that certain molecular alterations constitute a major additional putative diagnostic marker (e.g. highlighting a KIAA1549:BRAF fusion in pilocytic astrocytomas, as an example) (1).